The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 02, 2020
Filed:
Jan. 09, 2015
Applicant:
Rgenix, Inc., New York, NY (US);
Inventors:
Eduardo J. Martinez, Bryn Mawr, PA (US);
Bernd Kaiser, Wallingford, CT (US);
Sohail F. Tavazoie, New York, NY (US);
Isabel Kurth, New York, NY (US);
Foster Casimir Gonsalves, Long Island City, NY (US);
David M. Darst, Jr., New York, NY (US);
Masoud Fakhr Tavazoie, New York, NY (US);
Assignee:
Rgenix, Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 31/165 (2006.01); A61K 31/445 (2006.01); A61K 31/138 (2006.01); A61K 31/195 (2006.01); A61K 31/145 (2006.01); A61K 31/24 (2006.01); A61K 31/357 (2006.01); A61K 31/675 (2006.01); A61K 31/661 (2006.01); A61K 31/40 (2006.01); A61K 31/397 (2006.01); A61K 31/366 (2006.01); C07C 259/06 (2006.01); C07C 311/51 (2006.01); C07C 317/22 (2006.01); C07C 317/46 (2006.01); C07C 317/14 (2006.01); C07C 317/04 (2006.01); C07C 217/18 (2006.01); C07C 217/20 (2006.01); C07C 217/22 (2006.01); C07C 217/58 (2006.01); C07C 323/32 (2006.01); C07C 323/09 (2006.01); C07D 311/76 (2006.01); C07D 317/46 (2006.01); C07D 205/04 (2006.01); C07D 207/48 (2006.01); C07D 209/48 (2006.01); C07D 211/42 (2006.01); C07D 211/96 (2006.01); C07F 9/12 (2006.01); C07F 9/09 (2006.01); C07B 59/00 (2006.01); C07F 9/6571 (2006.01); C07F 9/6574 (2006.01); C07F 9/30 (2006.01);
U.S. Cl.
CPC ...
C07F 9/657172 (2013.01); A61K 31/138 (2013.01); A61K 31/145 (2013.01); A61K 31/165 (2013.01); A61K 31/195 (2013.01); A61K 31/24 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/445 (2013.01); A61K 31/661 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); C07B 59/004 (2013.01); C07C 217/18 (2013.01); C07C 217/20 (2013.01); C07C 217/22 (2013.01); C07C 217/58 (2013.01); C07C 259/06 (2013.01); C07C 311/51 (2013.01); C07C 317/04 (2013.01); C07C 317/14 (2013.01); C07C 317/22 (2013.01); C07C 317/46 (2013.01); C07C 323/09 (2013.01); C07C 323/32 (2013.01); C07D 205/04 (2013.01); C07D 207/48 (2013.01); C07D 209/48 (2013.01); C07D 211/42 (2013.01); C07D 211/96 (2013.01); C07D 311/76 (2013.01); C07D 317/46 (2013.01); C07F 9/09 (2013.01); C07F 9/094 (2013.01); C07F 9/12 (2013.01); C07F 9/304 (2013.01); C07F 9/65744 (2013.01); C07B 2200/05 (2013.01); C07C 2601/14 (2017.05);
Abstract
This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.